# A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Source: https://onco.cc/trials/nct06090266/  
OnCo record `nct06090266` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cemiplimab in metastatic cancer and melanoma, run by OncoResponse, Inc., now recruiting.

## Summary

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents is a phase 1/2 interventional study registered as NCT06090266 by OncoResponse, Inc., with 168 participants planned, started 2023-10-24 and due to reach its primary completion in 2026-08-01. Interventions recorded: OR502, Cemiplimab. Conditions listed: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06090266
- Phase: 1/2
- Setting: A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies
- Sponsor: OncoResponse, Inc.
- Enrolled: 168

## Sources

- ClinicalTrials.gov NCT06090266: https://clinicaltrials.gov/study/NCT06090266

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [OR502](https://onco.cc/drugs/or502/)

---
JSON: https://onco.cc/api/v1/entities/nct06090266.json